HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consider Environmental Risks During OTC Reclassification, Says Sweden's Drugs Regulator

Executive Summary

Sweden's national drugs regulator says environmental contamination risks should be reviewed as part of the overall benefit/risk assessment when reclassifying OTCs for sale outside pharmacies.

You may also be interested in...



GSCF Launches Global Self-Care Industry Sustainability Charter

The Global Self-Care Federation (GSCF) launches today its “Charter for Environmentally Sustainable Self-Care,” which it describes as the world’s “first commitment from the consumer health industry to drive sustainable self-care.”

Sweden Reverse-Switches Diclofenac Over Cardio Fears

Oral diclofenac will no longer be available without a prescription in Sweden after the national drug regulator judged that the potential adverse event risks were too high to justify continued OTC supply. Products from GSK and Mylan will be affected by the decision.

Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories

Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel